Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Equity Consolidated Statement of Equity

v3.22.1
Consolidated Statement of Equity Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Non-controlling Interests
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period, shares at Mar. 31, 2019   32,624,200              
Balance, beginning of period at Mar. 31, 2019 $ 348,949 $ 33 $ 223,040 $ 170,621 $ 4,204 $ (48,949)      
Issuance of common stock in exercise of stock options, shares   159,062              
Issuance of common stock in exercise of stock options 1,016   1,016            
Issuance of restricted stock as deferred compensation to employees and directors, shares             26,608    
Issuance of common stock in lieu of compensation, shares               59,570 47,378
Issuance of common stock as deferred compensation to employees 0 $ 0              
Stock compensation expense 4,960   4,960            
Excess tax deduction from stock options (969)   (969)            
Net income (loss) 11,938     11,938          
Foreign curency translation adjustment (15,485)         (15,485)      
Other 540         540      
Remeasurement of non-controlling interest     (306)   306        
Purchase of non-controlling interest (4,508)       (4,508)        
Income attributable to non-controlling interests (2)       (2)        
Balance, end of period, shares at Mar. 31, 2020   32,916,818              
Balance, end of period at Mar. 31, 2020 346,439 $ 33 227,741 182,559 0 (63,894)      
Issuance of common stock in exercise of stock options, shares   97,156              
Issuance of common stock in exercise of stock options 629   629            
Issuance of restricted stock as deferred compensation to employees and directors, shares             52,098    
Issuance of common stock in lieu of compensation, shares               88,254 71,482
Issuance of common stock as deferred compensation to employees 0 $ 0              
Stock compensation expense 3,728   3,728            
Excess tax deduction from stock options (784)   (784)            
Net income (loss) 877     877          
Foreign curency translation adjustment 28,615         28,615      
Other (632)   (8) 0   (640)      
Income attributable to non-controlling interests $ 0                
Balance, end of period, shares at Mar. 31, 2021 33,225,808 33,225,808              
Balance, end of period at Mar. 31, 2021 $ 378,872 $ 33 231,322 183,436 0 (35,919)      
Issuance of common stock in exercise of stock options, shares   8,100              
Issuance of common stock in exercise of stock options 97   97            
Issuance of restricted stock as deferred compensation to employees and directors, shares             32,136    
Issuance of common stock in lieu of compensation, shares               36,126 62,552
Issuance of common stock as deferred compensation to employees 0 $ 0              
Stock compensation expense 3,803   3,803            
Excess tax deduction from stock options (673)   (673)            
Net income (loss) 20,092     20,092          
Foreign curency translation adjustment (2,922)         (2,922)      
Other (65)   0     (65)      
Income attributable to non-controlling interests $ 0                
Balance, end of period, shares at Mar. 31, 2022 33,364,722 33,364,722              
Balance, end of period at Mar. 31, 2022 $ 399,204 $ 33 $ 234,549 $ 203,528 $ 0 $ (38,906)